Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Fate of lymphocytes after withdrawal of tofacitinib treatment.

Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G, Tommasini A.

PLoS One. 2014 Jan 9;9(1):e85463. doi: 10.1371/journal.pone.0085463. eCollection 2014.

2.

Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.

Martina MN, Ramirez Bajo MJ, Bañon-Maneus E, Moya Rull D, Hierro-Garcia N, Revuelta I, Campistol JM, Rovira J, Diekmann F.

Transplant Proc. 2016 Nov;48(9):3046-3052. doi: 10.1016/j.transproceed.2016.07.052.

PMID:
27932144
3.

The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.

Conklyn M, Andresen C, Changelian P, Kudlacz E.

J Leukoc Biol. 2004 Dec;76(6):1248-55. Epub 2004 Sep 15.

PMID:
15371489
4.

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y.

Rheumatology (Oxford). 2014 May;53(5):914-8. doi: 10.1093/rheumatology/ket466. Epub 2014 Jan 17.

PMID:
24441153
5.

Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.

Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y.

Ann Rheum Dis. 2014 Dec;73(12):2213-5. doi: 10.1136/annrheumdis-2014-205615. Epub 2014 Aug 25. No abstract available.

PMID:
25157177
6.

Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.

Piscianz E, Candilera V, Valencic E, Loganes C, Paron G, De Iudicibus S, Decorti G, Tommasini A.

Mol Med Rep. 2016 Jul;14(1):574-82. doi: 10.3892/mmr.2016.5263. Epub 2016 May 13.

PMID:
27175898
7.

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.

Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y.

Ann Rheum Dis. 2014 Dec;73(12):2192-8. doi: 10.1136/annrheumdis-2013-203756. Epub 2013 Sep 6.

PMID:
24013646
8.

Rough-Form Lipopolysaccharide Increases Apoptosis in Human CD4⁺ and CD8⁺ T Lymphocytes.

Nielsen JS, Larsson A, Ledet T, Turina M, Tønnesen E, Krog J.

Scand J Immunol. 2012 Feb;75(2):193-202. doi: 10.1111/j.1365-3083.2011.02613.x.

9.

In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, Dunbar P, Russo R, Little DM, Villinger T, Khowawisetsut L, Pattanapanyasat K, Villinger F, Ansari AA.

PLoS Pathog. 2014 Mar 6;10(3):e1003929. doi: 10.1371/journal.ppat.1003929. eCollection 2014 Mar.

10.

Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.

Tenorio EP, Saavedra R.

Int Immunopharmacol. 2005 Dec;5(13-14):1853-69. Epub 2005 Jun 21.

PMID:
16275621
11.

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y.

Arthritis Rheum. 2012 Jun;64(6):1790-8. doi: 10.1002/art.34329. Epub 2011 Dec 6.

12.

Effects of human soluble BAFF synthesized in Escherichia coli on CD4+ and CD8+ T lymphocytes as well as NK cells in mice.

Shan X, Chen L, Cao M, Xu L, Zhang S.

Physiol Res. 2006;55(3):301-7. Epub 2005 Aug 5.

13.

Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.

Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP.

J Clin Immunol. 2013 Apr;33(3):586-94. doi: 10.1007/s10875-012-9849-y. Epub 2012 Dec 28.

14.

Low stimulation of peripheral lymphocytes, following in vitro application of Emdogain.

Petinaki E, Nikolopoulos S, Castanas E.

J Clin Periodontol. 1998 Sep;25(9):715-20.

PMID:
9763326
15.

Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.

Vafadari R, Quaedackers ME, Kho MM, Mol WM, Chan G, Weimar W, Baan CC.

Transplantation. 2012 Sep 15;94(5):465-72. doi: 10.1097/TP.0b013e3182626b5a.

PMID:
22960764
16.

Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.

Okiyama N, Furumoto Y, Villarroel VA, Linton JT, Tsai WL, Gutermuth J, Ghoreschi K, Gadina M, O'Shea JJ, Katz SI.

J Invest Dermatol. 2014 Apr;134(4):992-1000. doi: 10.1038/jid.2013.476. Epub 2013 Nov 8.

17.

The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.

van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W, Baan CC.

Transplantation. 2009 Jan 15;87(1):79-86. doi: 10.1097/TP.0b013e31818bbea7.

PMID:
19136895
18.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142
19.

HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.

Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, Moretta A, Moretta L.

Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1172-7.

20.

Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.

Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD.

Am J Physiol Endocrinol Metab. 2006 May;290(5):E856-63. Epub 2005 Dec 13.

Supplemental Content

Support Center